Suppr超能文献

比较Biopince™活检针和Achieve™活检针时,实时超声引导下经皮非靶向肝活检的充分性

Adequacy of percutaneous non-targeted liver biopsy under real-time ultrasound guidance when comparing the Biopince™ and Achieve™ biopsy needle.

作者信息

Hall Thomas C, Deakin Claire, Atwal Gurprit Ss, Singh Rajeev K

机构信息

1 Department of Radiology, Royal Derby Hospital , Derby , UK.

2 Department of Cellular Pathology, Royal Derby Hospital , Derby , UK.

出版信息

Br J Radiol. 2017 Dec;90(1080):20170397. doi: 10.1259/bjr.20170397. Epub 2017 Oct 3.

Abstract

OBJECTIVE

The purpose of this study was to compare the adequacy rates of percutaneous liver biopsies, in parenchymal liver disease, using the Biopince (Argon Medical, Texas, TX, ) 16G and Achieve (Carefusion, Illinois, IL, USA) 18G biopsy needles in relation to the Royal College of Pathologists guidelines and to assess risk of complications.

METHODS

Data for all percutaneous non-targeted "medical" liver biopsies using the Biopince 16G and Achieve 18G biopsy needles were collected retrospectively over a 2-year period. Total biopsy core length and number of portal tracts was recorded along with adequacy of biopsy as assessed according to Royal College of Pathologists criteria.

RESULTS

In total, 194 percutaneous liver biopsies met the inclusion criteria; 53 using the Biopince needle and 141 using the Achieve needle. The mean total core length was 23 mm (SD 4.1) and 20 mm (SD 6.8) for the Biopince and Achieve needles, respectively (p = 0.0005). The mean number of portal tracts was 11 (SD 4.2) and 7 (SD 3.4) for the Biopince and Achieve needles, respectively (p < 0.0001). An adequate biopsy was obtained in 15 (31.3%) and 1 (1.3%) case using the Biopince and Achieve needles, respectively (p < 0.001). Compromised biopsies were obtained in 32 (66.7%) and 39 (50.6%) cases using the Biopince and Achieve needles, respectively. Inadequate biopsies were obtained in 1 (2%) and 37 (48.1%) cases using the Biopince and Achieve needles, respectively.

CONCLUSION

The Biopince 16G needle, when compared with the Achieve 18G needle, acquires a significantly greater total core length and number of portal tracts with significantly improved adequacy rates. There were no major complications associated with its use. Advances in knowledge: The Biopince 16G needle achieves significantly better specimen adequacy, when compared with the Achieve 18G needle and with no added major complications associated with its use.

摘要

目的

本研究旨在比较使用Biopince(氩气医疗公司,得克萨斯州,TX)16G活检针和Achieve(Carefusion公司,伊利诺伊州,IL,美国)18G活检针对实质性肝病进行经皮肝活检的取材充足率,并参照皇家病理学家学院的指南评估并发症风险。

方法

回顾性收集了2年期间内所有使用Biopince 16G和Achieve 18G活检针进行的经皮非靶向“医疗性”肝活检数据。记录活检组织芯的总长度、门静脉分支数量以及根据皇家病理学家学院标准评估的活检取材充足情况。

结果

共有194例经皮肝活检符合纳入标准;其中53例使用Biopince针,141例使用Achieve针。Biopince针和Achieve针的平均组织芯总长度分别为23毫米(标准差4.1)和20毫米(标准差6.8)(p = 0.0005)。Biopince针和Achieve针的平均门静脉分支数量分别为11个(标准差4.2)和7个(标准差3.4)(p < 0.0001)。使用Biopince针和Achieve针分别有15例(31.3%)和1例(1.3%)获得了充足的活检组织(p < 0.001)。使用Biopince针和Achieve针分别有32例(66.7%)和39例(50.6%)获得了质量欠佳的活检组织。使用Biopince针和Achieve针分别有1例(2%)和37例(48.1%)获得了取材不足的活检组织。

结论

与Achieve 18G针相比,Biopince 16G针获取的组织芯总长度和门静脉分支数量显著更多,取材充足率显著提高。使用该针未出现重大并发症。知识进展:与Achieve 18G针相比,Biopince 16G针能显著提高标本取材的充足性,且使用过程中未增加重大并发症。

相似文献

8
EUS-guided liver biopsy for parenchymal disease: a comparison of diagnostic yield between two core biopsy needles.
Gastrointest Endosc. 2016 Feb;83(2):347-52. doi: 10.1016/j.gie.2015.08.012. Epub 2015 Aug 13.
10
Prospective Study of the Impact of Liver Biopsy Core Size on Specimen Adequacy and Procedural Complications.
AJR Am J Roentgenol. 2018 Jan;210(1):183-188. doi: 10.2214/AJR.17.17792. Epub 2017 Nov 1.

引用本文的文献

1
Usefulness of Spleen Index and Alkaline Phosphatase Level for Predicting Post-Liver Biopsy Bleeding.
JGH Open. 2025 May 20;9(5):e70183. doi: 10.1002/jgh3.70183. eCollection 2025 May.
2
Modernizing metabolic dysfunction-associated steatotic liver disease diagnostics: the progressive shift from liver biopsy to noninvasive techniques.
Therap Adv Gastroenterol. 2024 Nov 14;17:17562848241276334. doi: 10.1177/17562848241276334. eCollection 2024.
3
Pathology Quality Control for Multiplex Immunofluorescence and Image Analysis Assessment in Longitudinal Studies.
Front Mol Biosci. 2021 Jul 30;8:661222. doi: 10.3389/fmolb.2021.661222. eCollection 2021.
5
Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis.
Dig Dis Sci. 2022 Jul;67(7):3366-3394. doi: 10.1007/s10620-021-07089-w. Epub 2021 Jun 15.
7
Enhancing the Value of Histopathological Assessment of Allograft Biopsy Monitoring.
Transplantation. 2019 Jul;103(7):1306-1322. doi: 10.1097/TP.0000000000002656.

本文引用的文献

4
Safety and effectiveness of blind percutaneous liver biopsy: analysis of 1412 procedures.
Hepat Mon. 2012 Jan;12(1):32-7. doi: 10.5812/kowsar.1735143x.4388. Epub 2012 Jan 20.
5
Reduced mortality rates following elective percutaneous liver biopsies.
Gastroenterology. 2010 Oct;139(4):1230-7. doi: 10.1053/j.gastro.2010.06.015. Epub 2010 Jun 12.
6
Percutaneous US-guided renal biopsy: a retrospective study comparing the 16-gauge end-cut and 14-gauge side-notch needles.
J Vasc Interv Radiol. 2010 Mar;21(3):357-61. doi: 10.1016/j.jvir.2009.11.005. Epub 2010 Feb 4.
7
Liver biopsy.
Hepatology. 2009 Mar;49(3):1017-44. doi: 10.1002/hep.22742.
10
A systematic review of the quality of liver biopsy specimens.
Am J Clin Pathol. 2006 May;125(5):710-21. doi: 10.1309/W3XC-NT4H-KFBN-2G0B.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验